Clinical test to predict effectiveness of antidepressants available next year

Two companies have partnered on a clinical depression support tool that predicts the effectiveness of antidepression treatments.

According to a press release from France-based Cerba HealthCare, Predictix, which was developed by Israeli digital health company Taliaz, will be available next year.

Predictix uses artificial intelligence to analyze multiple streams of patient data such as metabolic, demographic, genetic and clinical information, according to the release.

The tool was made developed to guide the management of depressed patients by presenting the medication with the best chance of therapeutic success the first time.

Doctors receive a personalized report for each patient predicting statistical efficacy, potential side effects and dosage based on the patient’s health record and pharmacogenetic makeup, according to the release. Predictix clinical research demonstrated a 72.2% response rate, and real-world data showed 90% of patients experienced clinical improvement after 8 weeks.

The solution will be available to patients by January throughout the Cerba HealthCare clinical routine pathology network, according to the release.